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Abstract: All modern vapor anesthetics are capable of carbon monoxide (CO) production as a result of interaction with 
desiccated strong base containing carbon dioxide absorbents. In desiccated absorbents, desflurane produces the highest 
concentrations of CO. Sevoflurane is known to produce the nephrotoxic compound A (CA) independently from water 
content of the carbon dioxide absorbent. The purpose of this study was to register the average CO concentrations in forty 
patients receiving anesthesia with desflurane or sevoflurane after implementation of a safety protocol adapted from 
Woehlck et al.. This protocol was developed to prevent desiccation of the strong base containing absorbent Drägersorb 
800 Plus
®
. Methods: In 40 patients a low-flow anesthesia was maintained using an oxygen/air mixture with either sevoflu-
rane or desflurane in combination with the CO2 absorbent Drägersorb 800 plus
®
. CO and CA production was measured in 
the inspiratory limb of the anesthesia machine using a portable gas chromatograph, with a sampling frequency of 12 sam-
ples per hour. Results: No carbon monoxide was measured in any of the desflurane or sevoflurane anesthesia’s. The mean 
concentration of CA for anesthesia with sevoflurane was 17.1 ± 5.5 parts per million. Conclusion: With the introduction 
of a safety protocol no carbon monoxide was measured in anesthesia performed with desflurane or sevoflurane. Com-
pound A is almost continuously detected in anesthetic procedures with the use of sevoflurane in very low concentrations. 
Implementation of a simple safety protocol possibly prevents desiccation of the absorbent and could subsequently reduce 
the risk of carbon monoxide intoxication. 
INTRODUCTION 
 All modern volatile anesthetic agents are known to be 
capable of carbon monoxide (CO) production as a result of 
their interaction with desiccated carbon dioxide absorbents 
containing strong bases  [1, 2]. Besides CO production, 
sevoflurane also produces other degradation products [3, 4], 
the most important being fluoromethyl-2,2-difluoro-1-
(trifluoromethyl)vinyl ether (Compound A). Compound A 
has proven to be nephrotoxic in rats [5, 6]. For CO produc-
tion to occur, the water content of the strong base containing 
carbon dioxide absorbent sodalime needs to be less than 
4,8% [1]. Compound A (CA) is also generated in combina-
tion with normally hydrated carbon dioxide absorbents [7]. 
In a previous laboratory study, we recorded very high con-
centrations of CO when using 3,0 vol% desflurane concomi-
tantly to a desiccated strong base containing absorbent 
Drägersorb 800 plus
®
. In that study [8], other volatile anes-
thetic agents produced CO at concentrations that were the 
lowest for sevoflurane, and that were increasing for halo-
thane, isoflurane and enflurane, respectively. In another 
study, we published the maximum concentrations of CA for 
sevoflurane in combination with seven different types of 
absorbents in fresh and desiccated condition [9]. That labora-
tory study evidenced only low concentrations of CA. 
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 Because of the theoretic possibility of production of high 
concentrations of CO from desflurane when used in combi-
nation with desiccated strong base containing absorbent 
Drägersorb 800 plus
®
 we implemented a safety protocol as 
described by Woehlck et al. [10], when desflurane was in-
troduced in our institution. We adapted this protocol to pre-
vent desiccation of the carbon dioxide absorbents, while still 
maintain the possibility of flushing the ventilating circuits of 
the anesthesia machines with a flow of air. Where Woehlck’s 
protocol used a ten minute flow of oxygen to dry expiratory 
limb flowmeters, our protocol used an one hour flow of air 
for flushing the ventilating circuits. Because of the small 
fraction of carbon dioxide in air this will generate water in-
side the absorbent, therefore preventing desiccation from the 
flow of air. All interventions of this protocol are described in 
Table 1. 
Table 1. Description of Interventions to Prevent Carbon Di-
oxide Absorbent Desiccation 
 
1. Anesthesia nurses were instructed to close the oxygen flow of the 
anesthesia machine after the operating program was finished 
2. An air flow could be used to flush the ventilating circuits of the 
anesthesia machine, limited in duration up to one hour.  
3. When at the start of the day a fresh gas flow of oxygen was de-
tected, the absorbent was changed immediately. 
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 In order to gain insight in regular clinical practice after 
implementing this safety protocol, we wanted to compare a 
potentially strong CO producing volatile anesthetic agent 
(desflurane) with a weak one (sevoflurane), and simultane-
ously investigate if the average CA concentrations in anes-
thetic procedures using sevoflurane were comparable to the 
low ranges found in our laboratory study. Therefore, the aim 
of this observational study was to register the average CO 
and CA concentrations in a group of patients receiving anes-
thesia with desflurane or sevoflurane. 
METHODS 
 This study was approved by the Committee on Human 
Research of the VU University Medical Center, where this 
study was performed. The study group included 40 non-
smoking patients categorized as American Society of Anes-
thesiologists physical status class 1 to 3, who were scheduled 
for a surgical procedure that would last at least ninety min-
utes. Patients younger than 18 years of age or suffering from 
terminal renal failure were excluded. All patients of one 
scheduled surgery program day, were randomly assigned 
with randomization envelopes, to receive anesthesia with 
either desflurane or sevoflurane. Forty patients scheduled for 
21 surgery program days were included. The anesthesia ma-
chine was a Dräger Cicero EM
®
 circle system. A standard 
bacterial humid filter was used. Patients were not premedi-
cated with a benzodiazepine, but received only 1000 mg 
paracetamol one hour before anesthesia was induced. After 
administration of 100% oxygen for several minutes, anesthe-
sia was induced by 3 μg/kg fentanyl, 1.5 to 2.5 mg/kg propo-
fol and 0.6 mg/kg rocuronium. Following tracheal intuba-
tion, the fresh gas flow rate (FGF) was set to 5 l/min and 
either desflurane or sevoflurane was introduced by a stan-
dard vaporizer. When a concentration of 4.0 vol% desflurane 
or 2.0 vol% sevoflurane was reached, the FGF was reduced 
at the discretion of the anesthesiologist to a minimum of 500 
and a maximum of 1000 ml/min. The ratio of the oxygen to 
air flow rates was adjusted to maintain the oxygen concen-
tration in the inspiratory limb above 30%. The anesthetic 
concentration was adjusted to maintain systolic blood pres-
sure within 20% (±) of baseline. If necessary, extra fentanyl 
was administered. The lungs were ventilated mechanically 
with a tidal volume of 8 ml/kg, with the ventilatory rate ad-
justed to maintain an end-tidal carbon dioxide concentration 
of 30-40 mmHg. 
Compound A and Carbon Monoxide Measurements 
 During anesthesia, gas was automatically sampled every 
5 minutes from the inspiratory limb of the anesthetic circuit 
at a rate of 100 ml/min during 10 seconds for measuring the 
concentrations of compound A and carbon monoxide with a 
portable gas chromatograph (Varian Chrompack CP 2003P). 
The gas chromatograph (GC) was equipped with a high sen-
sitivity thermal conductivity detector (TCD) and a Poraplot 
Q column for isolating CA and a Mollsieve 5A column for 
isolating CO. The reliability range of detection of this setup 
is 1 ppm to 1*10
6
 ppm with a margin of error of 10%. The 
GC was calibrated with a calibration mixture of 12 parts per 
million (ppm) CA in nitrogen (Scott specialty gasses, The 
Netherlands) derived from three millilitres of 99,6% pure 
CA (Baxter Pharmaceutical Products Inc., New Providence,  
 
NJ). Calibration for CO was performed using a mixture of 
210 ppm CO in nitrogen (Hoekloos specialty gasses, Di-
eren), and a second mixture of 981 ppm CO in nitrogen to 
confirm the linearity of the TCD. The gas chromatograph 
(GC) was connected to a desktop PC for control of the GC 
and data recording, analysis and storage. 
Analysis of Data 
 Analyzes were performed with SPSS for Windows ver-
sion 12.0. Measured values are expressed as means ± stan-
dard deviation. For comparison between samples before and 
after FGF reduction, the Mann-Whitney-U test was used 
with a significance level set at 5%. 
RESULTS 
 Demographic data of both groups are reported in Table 2. 
 For both groups, no CO was measured in any of the ex-
periments. CA was only detected in the sevoflurane group. 
Table 2. Number of Patients, Distribution of Sex, Mean Age 
and Anesthesia Duration 
 
 Desflurane Sevoflurane 
Number of patients 20 20 
Male/female 9/11 8/12 
Age (yr) 60.2 ± 15.2 54.6 ± 18.1 
Duration 2h21m± 28m 2h18m ± 30m 
Legend: yr=years, h=hours, m=minutes. Values for age and duration of anesthesia are 
mean ± SD. 
 
 The mean concentration of CA for all patients receiving 
sevoflurane anesthesia was 17.1 parts per million (ppm) with 
a standard deviation of 5.5 ppm. The minimum concentration 
of CA was 0.0 ppm and the maximum concentration 37.5 
ppm. Although CA was detected in most of the inspiratory 
limb of patients at the start of the experiment, four had a 
minimum CA concentration of 0.0 ppm at that time. For all 
anesthetic procedures using sevoflurane, an significant in-
crease in CA concentration was measured (Mann-Whitney-U 
p=0.01) during the 5 to 10 minutes following the FGF reduc-
tion. Subsequently, the CA concentration seemed to stabilize 
around the maximum value for the experiment. The mean 
CA concentration, as well as the minimum and maximum 
observed concentrations, is displayed for all anesthetic pro-
cedures with sevoflurane in Table 3. 
 The time course of change of measured mean CA con-
centrations for every five minute sample is depicted in Fig. 
(1). 
DISCUSSION 
 This study demonstrates that, during controlled clinical 
situations, desflurane and sevoflurane anesthesia is not asso-
ciated with carbon monoxide production, and that sevoflu-
rane anesthesia is associated with only small amounts of 
Compound A generation. In the desflurane group, we did not 
measure any CO in the inspiratory limb, although we would 
have expected at least a few ppm from the patients metabo-
lism  [11]. Possibly, these small concentrations of CO did  
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Table 3. Compound A Concentrations 
 
Anesthesia nr.  Mean [CA] Minimum [CA] Maximum [CA] 
1 16.3 ± 4.4 1.5 23.1 
2 20.9 ± 6.7 0.0 27.4 
3 18.0 ± 0.7 16.3 20.0 
4 14.0 ± 4.9 0.0 17.9 
5 13.6 ± 3.1 4.7 17.1 
6 14.8 ± 3.1 1.1 19.6 
7 15.9 ± 2.2 12.9 19.0 
8 18.4 ± 3.2 9.0 23.9 
9 18.2 ± 3.9 0.0 22.1 
10 16.1 ± 3.0 7.8 20.0 
11 21.2 ± 5.3 8.3 29.7 
12 21.3 ± 3.0 17.4 30.3 
13 15.1 ± 3.6 0.3 20.7 
14 13.4 ± 1.9 9.8 15.8 
15 14.7 ± 0.6 13.0 15.3 
16 28.8 ± 7.3 0.0 37.5 
17 10.9 ± 1.4 6.2 14.6 
18 13.7 ± 2.7 5.1 16.2 
19 17.0 ± 5.3 3.7 22.8 
20 17.9 ± 5.3 4.6 23.6 
Legend: Mean, minimum and maximum compound A (CA) concentrations from all 
anesthetic procedures using sevoflurane. Column 1 states the anesthesia number, col-
umn 2 the mean CA concentration ± SD for that experiment. Column 3 and 4 display 
respectively the minimum and maximum CA concentration. Concentrations in parts per 
million (ppm). 
 
not reach the inspiratory limb because of the small spill of 
gas in the semi-closed anesthesia system we used. The fact 
that no CO was produced in these anesthetic procedures 
means that the water content of the absorbent was always 
above 4,8% as demonstrated by Fang et al. [1]. This demon-
strates the rareness of complete desiccation of the absorbent 
in this clinical situation. This prevention of complete desic-
cation is probably due to the fact that the anesthesia nurses 
were instructed to use the safety protocol as described in the 
introduction. In this protocol, a flow of air is used when 
flushing the ventilating circuits of the anesthesia machines 
after surgery is necessary. A flow of air contains 0.03% of 
carbon dioxide that generates water when it reacts with the 
calcium hydroxide inside the absorbent, therefore preventing 
the absorbent from desiccating. Furthermore, a fresh gas 
flow of oxygen was never found in the anesthesia machine at 
the start of each study day, and the absorber did not have to 
be changed at any time. A limitation of this study is that this 
protocol was not tested against performance of anesthetic 
procedures without a safety protocol (as was current practice 
before introduction of desflurane in our institution) while 
using this strong base containing absorbent in combination 
with desflurane. For ethical reasons this option was not con-
sidered. Because of the lack of a control group in this study 
we cannot conclude that the safety protocol used is responsi-
ble for prevention of desiccation of the absorbent. However, 
the study by Woehlck et al. [10] did have a control group 
and that study demonstrated the relation between the imple-
mentation of a safety protocol and reduction of patient expo-
sure to carbon monoxide, indicating prevention of desicca-
tion of the absorbent. 
 In the anesthetic procedures performed with sevoflurane, 
we measured an increase of the measured CA concentration 
after the FGF was reduced from a flow of 5 l/min to a flow 
of 500 – 1000 ml/min. This is in accordance with other stud-
ies  [12-15] which demonstrated that a low flow will increase 
the amount of CA measured inside the circle system. This 
 
Fig. (1). Mean Compound A concentrations in parts per million (ppm) for every five minute sample. Time on the x-axis in hour:minutes. 
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variation of FGF may explain the observed large range in 
mean CA concentrations (between 13.4 and 28.8 ppm). 
 The CA concentrations measured in the present study are 
higher than in our previous laboratory study [9]. This is most 
probably due to the fact that we used 1.5 to 2.5 vol% 
sevoflurane in this study instead of the 0.8 vol% sevoflurane 
with 60% nitrous oxide in our laboratory study. A study by 
Yamakage et al.  [16] described a comparable increase of 
CA production when exposing Drägersorb 800 plus
®
 to 1 
and 2% sevoflurane respectively. The CA concentrations 
found in this study are comparable with concentrations found 
in other studies  [12, 17, 18] using the same concentrations 
of sevoflurane during low-flow anesthesia. In the first sam-
ples of four anesthetic procedures using sevoflurane (three of 
which were the first anesthesia of the day) no CA was meas-
ured. We assume that this lack of CA production was due to 
flushing of the anesthesia machine with air overnight or be-
tween anesthetic procedures. For the majority of anesthetic 
procedures, small amounts of CA were measured in the first 
sample, which were probably the result of CA formation 
from the previous anesthesia. 
 Although transient nephrotoxicity was demonstrated by 
Eger et al. [19] and Goldberg et al. [20] with respectively 
80-160 ppm/h and 240 ppm-h of CA exposure in humans, 
the majority of publications demonstrate no nephrotoxicity 
in humans with the use of sevoflurane in combination with 
any kind of absorbent  [21-23]. The results of this study, 
together with the results from our laboratory study  [9], con-
firm these observations. From these results we therefore 
conclude that sevoflurane can be safely used in low flow 
anesthesia in contradiction with the FDA recommendation to 
use a FGF of more than 2L/min. 
CONCLUSION 
 No carbon monoxide was measured during anesthetic 
procedures performed with desflurane or sevoflurane. This 
was possibly attributable to the use of a safety protocol, 
whereby the flow of air used to flush the ventilating circuits 
of the anesthesia machine does not desiccate the carbon di-
oxide absorbent. Compound A is almost continuously meas-
ured in anesthetic procedures with sevoflurane in very low 
concentrations in low flow anesthesia. 
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